Diagnosis: CancerSEEK and destroy - a blood test for early cancer detection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

29 citing papers in PubMed.

1. Development and validation of a serum peptidomic signature for early detection of asymptomatic ovarian cancer: A multi-center prospective study.Cell reports. Medicine · 2026
   Article
2. Non-Coding RNAs in Cancer: Decoding Regulatory Networks for Liquid Biopsy Applications.Genes · 2026
   Review
3. Longitudinal multiomics analysis of endocrine therapy effects and gut microbiota in breast cancer recurrence.Communications medicine · 2026
   Article
4. Virtual medicine: medical AI in human health and diseases.Military Medical Research · 2026
   Review
5. Signals Ahead: Balancing Cancer Detection Innovation and Evidence.Clinical journal of oncology nursing · 2025
   Article
6. Clinical Evaluation of a Multi-Omic Diagnostic Model for Early-Stage Ovarian Cancer Detection.Diagnostics (Basel, Switzerland) · 2025
   Article
7. Multicancer Early Detection Test Usage at Different National Comprehensive Cancer Network and National Cancer Institute-Designated Cancer Centers.Cureus · 2025
   Article
8. Socioeconomic impact of artificial intelligence-driven point-of-care testing devices for liquid biopsy in the OncoCheck system.Cancer metastasis reviews · 2025
   Review
9. Revolution of Circulating Tumor DNA: From Bench Innovations to Bedside Implementations.Current issues in molecular biology · 2025
   Review
10. Novel mRNA biomarker-based liquid biopsy for the detection of resectable pancreatic cancer.BMC cancer · 2025
    Article
11. Impact of clinical factors on accuracy of ovarian cancer detection via platelet RNA profiling.Blood advances · 2025
    Article
12. Advances in colorectal cancer screening: technological innovations, guideline discrepancies, and individualized strategies.Frontiers in oncology · 2025
    Review
13. Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring.Molecular cancer · 2024
    Review
14. Clinical Applications of Circulating Tumor DNA Profiling in GI Cancers.JCO oncology practice · 2024
    Review
15. A Comprehensive Review of Protein Biomarkers for Invasive Lung Cancer.Current oncology (Toronto, Ont.) · 2024
    Review
16. Technology and Future of Multi-Cancer Early Detection.Life (Basel, Switzerland) · 2024
    Review
17. Liquid biopsies and those three little words: finding the perfect match for the MTB.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023
    Article
18. Earlier Diagnosis of Pancreatic Cancer: Is It Possible?Cancers · 2023
    Review
19. Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation.International journal of molecular sciences · 2023
    Review
20. Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer.Biomedicines · 2023
    Review

Corrections and comments

• Comment on
  Detection and localization of surgically resectable cancers with a multi-analyte blood test.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as